Dr Morillo on Efficacy Data for Golcadomide in R/R Follicular Lymphoma

[Patients in] the 0.4-mg [golcadomide] plus rituximab [cohort] achieved a complete response rate of 75%, with an overall response rate of 97%. That is why the 0.4-mg [dose] was considered the recommended phase 2 dose…and these results are impressive in heavily pretreated patients.

Daniel Morillo, MD, a clinical investigator and consultant physician in the Department of Hematology and Hemotherapy at Fundación Jiménez Díaz University Hospital and the START Madrid–FJD Early Phase Unit, discussed efficacy data from the phase 1/2 CC-99282-NHL-001 trial (NCT03930953) evaluating the potential first-in-class oral CELMoD golcadomide (CC-99282) plus rituximab (Rituxan) in patients with relapsed/refractory follicular lymphoma, which were presented at the 2026 EHA Congress.

The two-part, multicenter, first-in-human CC-99282-NHL-001 study evaluated golcadomide as monotherapy and in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. In cohort D of part B, patients with relapsed/refractory follicular lymphoma received golcadomide at 0.2 mg or 0.4 mg on a 14-days-on/14-days-off schedule plus rituximab (n = 60). At a February 26, 2026, data cutoff, the median follow-up was 17.08 months (range, 2.1-35.1) in the intention-to-treat population, and patients were heavily pretreated, with a median of 3 prior lines of therapy.

In the efficacy-evaluable population, golcadomide at 0.4 mg plus rituximab (n = 36) elicited an objective response rate (ORR) of 97%, with a complete response (CR) rate of 75%; patients in the 0.2-mg cohort (n = 22) achieved an ORR of 77%, with a CR rate of 41%. Responses were durable at the 0.4-mg dose, with a median duration of response of 14.16 months (range, 0.0-24.7) and a median time to response of 1.9 months (range, 1.6-4.2); 81% of responders (n = 29) had responses lasting longer than 12 months.

These findings help support the design of the ongoing phase 3 GOLSEEK-4 study (NCT06911502) evaluating golcadomide plus rituximab as a fixed-duration, chemotherapy-free, outpatient option for patients with second- or later-line follicular lymphoma.